HC Wainwright Issues Optimistic Outlook for EYPT Earnings

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities research analysts at HC Wainwright lifted their Q3 2026 earnings estimates for Eyepoint Pharmaceuticals in a research note issued on Thursday, January 8th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.59) per share for the quarter, up from their previous estimate of ($0.65). The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($2.13) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q4 2026 earnings at ($0.53) EPS and FY2026 earnings at ($2.41) EPS.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. The business had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. Mizuho set a $28.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $29.25.

Eyepoint Pharmaceuticals Trading Down 0.1%

Eyepoint Pharmaceuticals stock opened at $15.93 on Monday. The stock has a fifty day moving average price of $15.55 and a 200 day moving average price of $13.10. Eyepoint Pharmaceuticals has a 52 week low of $3.91 and a 52 week high of $19.11. The firm has a market capitalization of $1.32 billion, a P/E ratio of -5.33 and a beta of 1.63.

Institutional Trading of Eyepoint Pharmaceuticals

Several large investors have recently bought and sold shares of EYPT. Nisa Investment Advisors LLC lifted its position in shares of Eyepoint Pharmaceuticals by 1,636.5% during the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock worth $27,000 after purchasing an additional 2,733 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth $50,000. Russell Investments Group Ltd. acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter worth $76,000. Tower Research Capital LLC TRC boosted its position in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after buying an additional 5,967 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at about $100,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Insider Buying and Selling

In other news, insider Ramiro Ribeiro sold 42,544 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.46% of the stock is owned by company insiders.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.